MDV3100 for the treatment of prostate cancer

@article{Mukherji2012MDV3100FT,
  title={MDV3100 for the treatment of prostate cancer},
  author={Deborah Mukherji and Carmel Jo Pezaro and Johann de-Bono},
  journal={Expert Opinion on Investigational Drugs},
  year={2012},
  volume={21},
  pages={227 - 233}
}
Introduction: MDV3100 is a rationally designed androgen receptor antagonist, which has recently been shown to improve survival in men with metastatic castration-resistant prostate cancer previously treated with docetaxel chemotherapy. Drug development for advanced prostate cancer is advancing at a rapid pace with four other novel therapies (abiraterone, cabazitaxel, alpharadin and sipuleucel-T) also shown to improve overall survival in large randomised studies. Areas covered: This review will… Expand
The role of enzalutamide in the treatment of castration-resistant prostate cancer.
TLDR
Enzalutamide is an androgen receptor signaling inhibitor that has been shown to improve survival in men with metastatic castration-resistant prostate cancer previously treated with chemotherapy and is discussed in this article. Expand
Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.
TLDR
Current concepts and challenges behind targeting continued androgen receptor signaling in castration-resistant prostate cancer are reviewed and an overview of recently completed and ongoing clinical trials of novel hormonal agents are provided, with a focus on abiraterone acetate and enzalutamide. Expand
Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer
TLDR
It is shown that AR-signalling-competent human CRPC cell lines are preferentially sensitive to bromodomain and extraterminal (BET) inhibition, which provides a novel epigenetic approach for the concerted blockade of oncogenic drivers in advanced prostate cancer. Expand
Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer.
TLDR
The use of PSA criteria alone should not be used to determine the progression of disease; instead, PSA should be evaluated in combination with other clinical data. Expand
Prostate cancer vaccines
TLDR
This review will examine key aspects of the evolution of prostate cancer vaccines, which provides an accurate prototype for other cancers, and the challenges the authors face. Expand
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer☆
Highlights • New drugs approved for treatment of castration resistant prostate cancer.• Prime targets: androgen receptor, bone cells, cell division, immune system.• Several promising drugsExpand
Role of the EpCAM (CD326) in prostate cancer metastasis and progression
TLDR
The implications of the newly identified roles of EpCAM in terms of its diagnostic and metastatic relevance to CaP are discussed and emerging and innovative approaches to the management of the disease and expanding potential therapeutic applications ofEpCAM for targeted strategies in future CaP therapy are explored. Expand
CDK7 inhibition suppresses Castration-Resistant Prostate Cancer through MED1 inactivation.
TLDR
It is demonstrated that CDK7 inhibition selectively targets MED1-mediated, AR-dependent oncogenic transcriptional amplification, thus representing a potential new approach for the treatment of CRPC. Expand
Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
TLDR
The potential use of the PI3K/Akt/mTOR pathway inhibitors as radiosensitizers in the treatment of CaP radioresistance in preclinical studies to explore novel approaches for future clinical trials are discussed. Expand
Androgen Suppression: The Good, The Bad and The Ugly
TLDR
The androgen receptor, a member of the family of nuclear receptors, is a key modulator in development of prostate cancer and of prostatecancer progression and is a well-established target for therapeutic intervention in prostate cancer. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 46 REFERENCES
Abiraterone and increased survival in metastatic prostate cancer.
TLDR
The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. Expand
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
TLDR
The results of this phase 1-2 trial validate in man preclinical studies implicating sustained androgen-receptor signalling as a driver in this disease. Expand
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
TLDR
The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer. Expand
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
TLDR
There is an urgent need for new agents that provide palliation and improve survival in men with metastatic prostate cancer, including chemotherapy with docetaxel for patients with CRPC. Expand
CYP17 inhibition as a hormonal strategy for prostate cancer
TLDR
A novel, selective, irreversible inhibitor of CYP17 called abiraterone acetate, which is more than 20 times more potent than ketoconazole, is designed and is rapidly progressing from phase II to phase III trials, in view of its high level of antitumor activity. Expand
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.
TLDR
Diethylstilbesterol appears to be an active agent for second-line hormone therapy for metastatic prostate cancer and should be considered for development under the orphan drug strategy. Expand
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
TLDR
The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T. Expand
The evolving role of estrogen therapy in prostate cancer.
  • W. Oh
  • Medicine
  • Clinical prostate cancer
  • 2002
TLDR
There remain many unanswered questions about the role of estrogen therapy in prostate cancer, including differences between specific drugs, optimal dose, timing, and patient selection. Expand
Combined androgen blockade with bicalutamide for advanced prostate cancer
A previously reported, double‐blind, randomized, multicenter phase 3 trial in 205 patients with stage C/D prostate cancer compared combined androgen blockade (CAB) with luteinizing hormone‐releasingExpand
Management of advanced prostate cancer after first-line chemotherapy.
TLDR
Second-line hormonal maneuvers including glucocorticoids, ketoconazole, and estrogens can lead to further palliation in some patients, and there are provocative data that chemotherapy might restore hormonal sensitivity in a subset of patients. Expand
...
1
2
3
4
5
...